

Special Issue

Advances in the Use of Nanoparticles for Vaccine Platform Development: 2nd Edition

Message from the Guest Editor

Vaccination is effective in preventing diseases. New vaccine candidates have been developed, including nucleic acids and subunit vaccines. These innovations have led to vaccines that induce specific immune responses with fewer side effects. However, newer-generation vaccines sometimes show lower immunogenicity. Nanoparticle-based formulations enhance immune responses. These systems protect vaccine candidates, improve stability, and have adjuvant properties. They target antigen-presenting cells and can elicit immune responses, with flexibility for various administration routes. Manufacturing methods are advancing. This Special Issue invites original research and review articles focusing on the preclinical and clinical development of advanced nanoparticle delivery systems. These may include liposomes; lipid-based, polymeric, gold, inorganic, and biomimetic nanoparticles; virus-like particles; self-assembled proteins; and other forms, including carbon-based nanoparticles such as carbon nanotubes and graphene.

Guest Editor

Prof. Dr. Imran Saleem

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

Deadline for manuscript submissions

30 November 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/231911

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).